 Furthermore, before the development of Aldurazyme, there were no drugs to treat MPS I, allowing BioMarin to be first-to-market with its new pharmaceutical.Since the release of Aldurazyme, one more drug has been released to treat MPS; Elaprase is a treatment for MPS II.In 2016, Aldurazyme had an average cost-per-patient of $355,816.